Pharmacological therapy for cystic fibrosis: From bench to bedside

Frédéric Becq, Marcus A. Mall, David N. Sheppard, Massimo Conese, Olga Zegarra-Moran

Research output: Contribution to journalArticle

Abstract

With knowledge of the molecular behaviour of the cystic fibrosis transmembrane conductance regulator (CFTR), its physiological role and dysfunction in cystic fibrosis (CF), therapeutic strategies are now being developed that target the root cause of CF rather than disease symptoms. Here, we review progress towards the development of rational new therapies for CF. We highlight the discovery of small molecules that rescue the cell surface expression and defective channel gating of CF mutants, termed CFTR correctors and CFTR potentiators, respectively. We draw attention to alternative approaches to restore epithelial ion transport to CF epithelia, including inhibitors of the epithelial Na+ channel (ENaC) and activators of the Ca2+-activated Cl- channel TMEM16A. The expertise required to translate small molecules identified in the laboratory to drugs for CF patients depends on our ability to coordinate drug development at an international level and our ability to provide pertinent biological information using suitable disease models.

Original languageEnglish
JournalJournal of Cystic Fibrosis
Volume10
Issue numberSUPPL. 2
DOIs
Publication statusPublished - Jul 2011

Fingerprint

Cystic Fibrosis
Pharmacology
Cystic Fibrosis Transmembrane Conductance Regulator
Therapeutics
Epithelial Sodium Channels
Ion Transport
Pharmaceutical Preparations
Epithelium

Keywords

  • Airway surface fluid
  • CFTR
  • CFTR correctors
  • CFTR potentiators
  • ENaC
  • F508del

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Pediatrics, Perinatology, and Child Health

Cite this

Becq, F., Mall, M. A., Sheppard, D. N., Conese, M., & Zegarra-Moran, O. (2011). Pharmacological therapy for cystic fibrosis: From bench to bedside. Journal of Cystic Fibrosis, 10(SUPPL. 2). https://doi.org/10.1016/S1569-1993(11)60018-0

Pharmacological therapy for cystic fibrosis : From bench to bedside. / Becq, Frédéric; Mall, Marcus A.; Sheppard, David N.; Conese, Massimo; Zegarra-Moran, Olga.

In: Journal of Cystic Fibrosis, Vol. 10, No. SUPPL. 2, 07.2011.

Research output: Contribution to journalArticle

Becq, F, Mall, MA, Sheppard, DN, Conese, M & Zegarra-Moran, O 2011, 'Pharmacological therapy for cystic fibrosis: From bench to bedside', Journal of Cystic Fibrosis, vol. 10, no. SUPPL. 2. https://doi.org/10.1016/S1569-1993(11)60018-0
Becq, Frédéric ; Mall, Marcus A. ; Sheppard, David N. ; Conese, Massimo ; Zegarra-Moran, Olga. / Pharmacological therapy for cystic fibrosis : From bench to bedside. In: Journal of Cystic Fibrosis. 2011 ; Vol. 10, No. SUPPL. 2.
@article{b18c14a968ea48e49431e8ff4d2518c6,
title = "Pharmacological therapy for cystic fibrosis: From bench to bedside",
abstract = "With knowledge of the molecular behaviour of the cystic fibrosis transmembrane conductance regulator (CFTR), its physiological role and dysfunction in cystic fibrosis (CF), therapeutic strategies are now being developed that target the root cause of CF rather than disease symptoms. Here, we review progress towards the development of rational new therapies for CF. We highlight the discovery of small molecules that rescue the cell surface expression and defective channel gating of CF mutants, termed CFTR correctors and CFTR potentiators, respectively. We draw attention to alternative approaches to restore epithelial ion transport to CF epithelia, including inhibitors of the epithelial Na+ channel (ENaC) and activators of the Ca2+-activated Cl- channel TMEM16A. The expertise required to translate small molecules identified in the laboratory to drugs for CF patients depends on our ability to coordinate drug development at an international level and our ability to provide pertinent biological information using suitable disease models.",
keywords = "Airway surface fluid, CFTR, CFTR correctors, CFTR potentiators, ENaC, F508del",
author = "Fr{\'e}d{\'e}ric Becq and Mall, {Marcus A.} and Sheppard, {David N.} and Massimo Conese and Olga Zegarra-Moran",
year = "2011",
month = "7",
doi = "10.1016/S1569-1993(11)60018-0",
language = "English",
volume = "10",
journal = "Journal of Cystic Fibrosis",
issn = "1569-1993",
publisher = "Elsevier",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Pharmacological therapy for cystic fibrosis

T2 - From bench to bedside

AU - Becq, Frédéric

AU - Mall, Marcus A.

AU - Sheppard, David N.

AU - Conese, Massimo

AU - Zegarra-Moran, Olga

PY - 2011/7

Y1 - 2011/7

N2 - With knowledge of the molecular behaviour of the cystic fibrosis transmembrane conductance regulator (CFTR), its physiological role and dysfunction in cystic fibrosis (CF), therapeutic strategies are now being developed that target the root cause of CF rather than disease symptoms. Here, we review progress towards the development of rational new therapies for CF. We highlight the discovery of small molecules that rescue the cell surface expression and defective channel gating of CF mutants, termed CFTR correctors and CFTR potentiators, respectively. We draw attention to alternative approaches to restore epithelial ion transport to CF epithelia, including inhibitors of the epithelial Na+ channel (ENaC) and activators of the Ca2+-activated Cl- channel TMEM16A. The expertise required to translate small molecules identified in the laboratory to drugs for CF patients depends on our ability to coordinate drug development at an international level and our ability to provide pertinent biological information using suitable disease models.

AB - With knowledge of the molecular behaviour of the cystic fibrosis transmembrane conductance regulator (CFTR), its physiological role and dysfunction in cystic fibrosis (CF), therapeutic strategies are now being developed that target the root cause of CF rather than disease symptoms. Here, we review progress towards the development of rational new therapies for CF. We highlight the discovery of small molecules that rescue the cell surface expression and defective channel gating of CF mutants, termed CFTR correctors and CFTR potentiators, respectively. We draw attention to alternative approaches to restore epithelial ion transport to CF epithelia, including inhibitors of the epithelial Na+ channel (ENaC) and activators of the Ca2+-activated Cl- channel TMEM16A. The expertise required to translate small molecules identified in the laboratory to drugs for CF patients depends on our ability to coordinate drug development at an international level and our ability to provide pertinent biological information using suitable disease models.

KW - Airway surface fluid

KW - CFTR

KW - CFTR correctors

KW - CFTR potentiators

KW - ENaC

KW - F508del

UR - http://www.scopus.com/inward/record.url?scp=79958104493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958104493&partnerID=8YFLogxK

U2 - 10.1016/S1569-1993(11)60018-0

DO - 10.1016/S1569-1993(11)60018-0

M3 - Article

C2 - 21658632

AN - SCOPUS:79958104493

VL - 10

JO - Journal of Cystic Fibrosis

JF - Journal of Cystic Fibrosis

SN - 1569-1993

IS - SUPPL. 2

ER -